The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
about
Intravital FRET imaging of tumor cell viability and mitosis during chemotherapyTumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell linesLiposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathwaysThe influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenograftsDatabase screening of herbal monomers regulating autophagy by constructing a "disease-gene-drug" networkRadiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.The Cancer Chemotherapeutic Paclitaxel Increases Human and Rodent Sensory Neuron Responses to TRPV1 by Activation of TLR4Dehydroandrographolide, an iNOS inhibitor, extracted from Andrographis paniculata (Burm.f.) Nees, induces autophagy in human oral cancer cells.The pharmacological bases of the antiangiogenic activity of paclitaxel.Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral NeuropathyStrategies for the synthesis of the novel antitumor agent peloruside A.The impact of T-cell immunity on ovarian cancer outcomes.Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.Polyphyllin G induce apoptosis and autophagy in human nasopharyngeal cancer cells by modulation of AKT and mitogen-activated protein kinase pathways in vitro and in vivo.Paclitaxel nanoparticle awakens immune system to fight against cancer.Synthesis and anti-inflammatory evaluation of novel paclitaxel analogs.Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.Cell migration within confined sandwich-like nanoenvironments.Docetaxel modulates the delayed rectifier potassium current (IK) and ATP-sensitive potassium current (IKATP) in human breast cancer cells.Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysisMiR-34c oligonucleotide enhances chemosensitivity of Ishikawa cell to cisplatin by inducing apoptosis.Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular BioenergeticsAntitumor activities of extracts and compounds from water decoctions of Taxus cuspidata.Emotional acceptance, inflammation, and sickness symptoms across the first two years following breast cancer diagnosis.Microtubule-stabilizing agents delay the onset of EAE through inhibition of migration.ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats.High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.Comparison of serious adverse events between the original and a generic docetaxel in breast cancer patients.The High Costs of Low-Grade Inflammation: Persistent Fatigue as a Consequence of Reduced Cellular-Energy Availability and Non-adaptive Energy Expenditure.Hazel and other sources of paclitaxel and related compoundsPreparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery
P2860
Q27319918-005C4C9D-7662-4E6F-9BA9-ECF3384A0F3AQ33377058-E69FCF29-7141-4979-86C7-E4B36BDC2D64Q33732552-F5602470-7D91-4F5E-AFF3-74FAE7354FCCQ33746626-863778B7-F2B4-4A2F-8AEC-B8518E59AD23Q34303312-7FC04FE2-5CFA-41BB-81F3-D801D02391D5Q34967840-9462FDB8-0AED-4DBF-AC4F-765B0EF24F09Q35964863-8E16228A-F063-44E5-A3AE-F9DAD88C6204Q36106866-9D6267C4-5A45-4C54-976F-C5167D1BB2B1Q36544433-9556933D-40AF-4689-BE96-3A5E50C06A58Q36927558-05884929-A309-4DFE-8CA8-F4A64118D504Q36965080-A298E2CE-4B2A-4FA3-A6A7-77A3F38E81EDQ37081502-C269B754-676C-4865-85D1-BC0E65DF674BQ37088098-61EABF7D-E1D4-4A0F-8696-D65C5D093F6BQ37118142-85352BC3-9F8A-4F2F-81C4-C8F9671EAD7EQ37251547-FC0FC3CB-CDC7-42FA-A54E-04E88D91A3AEQ37480340-F76B67D6-3C6B-4EDA-91BE-DAD7B4373529Q37688524-75F182A6-6A54-455F-AC67-C128ADE394C9Q38688207-04571CDB-0A64-4CE0-AF08-DE0774A30DCAQ38739830-EBA0C989-B7EB-4B82-BE12-7C6222EDADDBQ38772271-E8DC893C-57EF-44C4-AB71-D944F2C95A5FQ38894097-80D2E199-61A7-4775-8F15-3C75FD0ACD68Q38938154-714F6F4A-BD22-4196-8104-473F525D7784Q39139831-5698EB67-75CF-4A4F-939C-409DC21B2E25Q39193935-2FD78F57-1D56-4FD8-8D78-EC986C80AE0BQ39374624-0786506C-4070-45D8-928A-F3DE092383BAQ39634184-C0503B24-BF5F-4CC5-9890-4AD34D87447FQ42132869-297A4EFE-3B23-4307-A684-971BCB77BDA6Q46438072-6166FD82-DCD5-4251-BB6E-5F345649679DQ46559935-786E39F0-3948-46F4-991E-837C09ACF022Q47811425-B2E4487E-74D3-4D65-BED8-E9204B7A34A7Q48119796-C4EDC2CB-B378-4188-A8F8-F533DBCE8A3AQ55383738-0E4123E5-5C40-4937-9FB5-848A1B936E71Q57003263-807BB66D-230C-4B08-91F5-E90DD951C61CQ59113498-65462B9F-DF99-422B-AE97-4C31C0E87B1F
P2860
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@ast
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@en
type
label
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@ast
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@en
prefLabel
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@ast
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@en
P1476
The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.
@en
P2093
F A Fitzpatrick
Richard Wheeler
P304
P356
10.1016/J.INTIMP.2003.08.007
P577
2003-12-01T00:00:00Z